GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...

The study involved 242 Computed Tomography (CT) images of patients with CRSwNP, constructing a high-quality professional CRSwNP database for the training, validation, and testing of neural networks.

The staining intensity of IHC was analysed using Image J software (National Institute of Health ... of tissues obtained from our Apc mutant NP mice as well as from CRSwNP patients, we provide evidence ...

While going through the phone, detectives said they found several inappropriate images of female patients in the bathroom and taking a shower.Keep up with the latest news and weather by ...

Bilateral versus unilateral cases of chronic rhinosinusitis with nasal polyps have notable clinical and laboratory ...

It takes about 3 months to heal from traditional cardiovascular surgery. Physician's Regional says their patients can heal in as soon as 10 days due to their cardiac surgery system.

GSK plc announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted indications are for ...

If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing Submissions based on data from positive SWIFT and ANCHOR trials SWIFT-1 and -2 showed depemokimab reduced ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Similarly, the ANCHOR trials showed that depemokimab effectively reduced nasal polyp size and obstruction in CRSwNP patients compared to placebo. Depemokimab, a monoclonal antibody targeting ...